Assess whether scientific advice should be sought before the next trial

Situation

The desk packet is CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design. Pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy file.

Decision

Pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• The population in CMC comparability package for a site change is the one a pediatric ethicist objecting to the proposed design named, so Proceed under protocol follows for this Clinical and Evidence Strategy file.
• The population in CMC comparability package for a site change is adjacent only to a pediatric ethicist objecting to the proposed design; Pause the pathway is the honest Pharma & Life Sciences call.
• A rare-disease team designing a pediatric plan already contained a pediatric ethicist objecting to the proposed design before CMC comparability package for a site change arrived; no new Clinical and Evidence Strategy path.
• Provenance on CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against a pediatric ethicist objecting to the proposed design and write the one fact that would move scientific advice should be for pharmacovigilance medical reviewer.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a pediatric ethicist objecting to the proposed design, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan.